Cite
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
MLA
Oh, S. C., et al. “A Phase II Study of Biweekly Dose-Intensified Oral Capecitabine plus Irinotecan (BXELIRI) for Patients with Advanced or Metastatic Gastric Cancer.” British Journal of Cancer, vol. 96, no. 10, May 2007, pp. 1514–19. EBSCOhost, https://doi.org/10.1038/sj.bjc.6603752.
APA
Oh, S. C., Sur, H. Y., Sung, H. J., Choi, I. K., Park, S. S., Seo, J. H., Jeen, Y. T., Chun, H. J., Shin, S. W., Mok, Y. J., Kim, J. S., & Kim, Y. H. (2007). A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. British Journal of Cancer, 96(10), 1514–1519. https://doi.org/10.1038/sj.bjc.6603752
Chicago
Oh, S. C., H. Y. Sur, H. J. Sung, I. K. Choi, S. S. Park, J. H. Seo, Y. T. Jeen, et al. 2007. “A Phase II Study of Biweekly Dose-Intensified Oral Capecitabine plus Irinotecan (BXELIRI) for Patients with Advanced or Metastatic Gastric Cancer.” British Journal of Cancer 96 (10): 1514–19. doi:10.1038/sj.bjc.6603752.